Clinical trials
Phase 2/3 Cholangiocarcinoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 3 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 5 |
| Active, not recruiting | 4 |
| Recruiting | 4 |
| Not yet recruiting | 2 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Air Force Military Medical University, China | 1 |
| Amsterdam UMC, location VUmc | 1 |
| Compass Therapeutics | 1 |
| Delcath Systems Inc. | 1 |
| ECOG-ACRIN Cancer Research Group | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| Gruppo Oncologico del Nord-Ovest | 1 |
| Guangzhou Medical University | 1 |
| Mara Veenstra, MD | 1 |
| RenJi Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cholangiocarcinoma | 17 |
| Biliary Tract Neoplasms | 4 |
| Bile Duct Neoplasms | 2 |
| Gallbladder Neoplasms | 2 |
| Klatskin Tumor | 2 |
| Adenocarcinoma | 1 |
| Bile Duct Diseases | 1 |
| Biliary Tract Diseases | 1 |
| Camurati-Engelmann Syndrome | 1 |
| Carcinoma | 1 |
Trials
Showing 51 to 17 of 17. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.